DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

LH·Labcorp Holdings Inc.

$.
+. (+.%)
After Hours
High
$290.65
Open
$282.46
Market Cap
23.24B
52W High
$293.72
Low
$279.02
P. Close
$283.39
P/E
24.68
52W Low
$241.81
Fwd P/E
14.60
DailyIQ Est.
$319.43
Technical Score (1D)
91
BUY
News Sentiment
67
BULLISH
B of A Securities raised Labcorp’s price target to $320, reflecting confidence that the company’s earnings outlook will improve as lab service demand remains strong. Baird followed suit, lifting its target to $338 and underscoring belief that growth and cost‑control initiatives will sustain profitability. The dual upgrades suggest consensus that revenue from diagnostic testing will stay robust, which could support the stock in the short term. Labcorp’s declaration of a $0.72 quarterly dividend adds a modest yield, signaling cash‑flow strength that may attract income‑focused investors and help stabilize the share price around the ex‑dividend date. The dividend also provides a cushion against short‑term earnings volatility. The company will report Q2 2026 results on July 30, with a 9:00 a.m. ET webcast, offering a key data point for evaluating revenue trends and margin performance. Analysts expect low‑double‑digit earnings growth, driven by higher test volumes and the impact of recent acquisitions, which could validate the upgraded price targets. The FDA approval and Medicare coverage of the ColoSense at‑home colorectal test, announced earlier, may boost future test volumes and revenue, though its effect will likely materialize over a longer horizon. Traders should watch the earnings release for guidance on revenue mix, cost control, and ColoSense uptake, as well as any updates on foreign‑exchange hedging that could influence profitability.
Earnings Summary
Labcorp Holdings Inc. (LH) is a leading provider of comprehensive laboratory services, operating through Diagnostics Laboratories and Biopharma Laboratory Services segments that deliver routine and specialized testing to healthcare providers, pharmaceutical companies, and managed care organizations, while its online and mobile platforms enhance patient and clinician access. The company functions within the healthcare sector, specifically the diagnostics and research industry, and its earnings are driven by test volumes, pricing power, and cost‑control initiatives. In the most recent quarters, Labcorp posted EPS that consistently beat estimates: 3.45 in Q4 2024 versus 3.39206, 3.84 in Q1 2025 versus 3.73484, 4.35 in Q2 2025 versus 4.17917, 4.18 in Q3 2025 versus 4.13813, 4.07 in Q4 2025 versus 3.94198, and 4.25 in Q1 2026 versus 4.2163, marking six consecutive EPS beats; revenue grew modestly from $3.3294 B in Q4 2024 to $3.3451 B in Q1 2025, accelerated to $3.5273 B in Q2 2025 and $3.5635 B in Q3 2025, dipped slightly to $3.5158 B in Q4 2025, and rebounded to $3.5376 B in Q1 2026, reflecting steady but uneven growth. Historically, Labcorp has maintained a streak of EPS beats while revenue has hovered in the $3.3–$3.6 B range, indicating disciplined cost management and consistent test volume expansion. Recent analyst activity has been positive: B of A Securities and Baird both raised price targets to $320 and $338, respectively, citing confidence in earnings outlook and cost‑control initiatives, and the company declared a $0.72 quarterly dividend, reinforcing cash‑flow strength; FDA approval and Medicare coverage of the ColoSense at‑home colorectal test were also highlighted as potential long‑term revenue drivers. Investors should watch the upcoming Q2 2026 earnings for guidance on revenue mix, margin trends, and the adoption trajectory of ColoSense, as well as any updates on currency hedging and specialty testing expansion, since these factors will shape the next quarter’s performance and valuation.

EPS

EstBeatMiss
$3.58$3.92$4.25$4.59$4.92Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.77 - -
Q1'26$4.22$4.25+0.8%
Q4'25$3.94$4.07+3.2%
Q3'25$4.14$4.18+1.0%
Q2'25$4.18$4.35+4.1%
Q1'25$3.73$3.84+2.8%

Revenue

EstBeatMiss
$3.3B$3.4B$3.6B$3.7B$3.9BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.8B - -
Q1'26$3.6B$3.5B-2.0%
Q4'25$3.6B$3.5B-1.2%
Q3'25 - $3.6B -
Q2'25 - $3.5B -
Q1'25 - $3.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

LH Stock Snapshot

LH is currently trading at $283.36, giving Labcorp Holdings Inc. a market cap of 23.24B and a P/E ratio of 24.7. Today's range spans $279.02–$290.65, with shares opening at $282.46 and moving down $0.03 (0.0%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 67/100.

Over the past year LH has traded between $241.81 and $293.72 - the current price is +17.2% off the 52-week low and -3.5% from the high. 30 analysts cover the stock with a Buy consensus and a mean 12-month target of $312.18 (range $270.00–$340.00), implying upside of +10.2%.

If you're looking for bullish momentum in Healthcare, LH is putting up the numbers: 91/100 technical score, BUY signal, bullish sentiment at 67/100. Price: $283.36 (in the upper portion of its 52-week range). (P/E: 24.7) The 23.24B market cap keeps it in play for institutional position sizes, and the $241.81–$293.72 annual range shows this stock can make real moves when it gets directional conviction behind it.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (91/100) and news sentiment (67/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $283.36 (in the upper portion of its 52-week range), LH's position within the $241.81–$293.72 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.